Biotech Values

[DewDiligence]

More from RVNC's PR on phase-2 trial in plantar fascitis:

http://finance.yahoo.com/news/revance-announces-initiation-phase-2-120000127.html

…Revance has the opportunity to be a first mover for this indication and other musculoskeletal disorders,” said Dan Browne, President and Chief Executive Officer at Revance. “No botulinum toxin is approved for treating plantar fasciitis; however, the clinical endpoints are well validated. Published estimates place the annual U.S. evaluation and treatment market for plantar fasciitis at more than $250 million, and we believe the market could grow significantly larger if patients had a compelling neurotoxin treatment option.”

This Phase 2 prospective, randomized, double-blinded, placebo-controlled study will evaluate the safety and efficacy of a single administration of Revance’s investigational drug candidate DaxibotulinumtoxinA for Injection (RT002) in reducing the signs and symptoms of plantar fasciitis. The study is expected to enroll approximately 60 subjects in the United States. The study’s primary efficacy endpoint is the improvement in the American Orthopaedic Foot and Ankle Score (AOFAS). Subjects will be followed for 16 weeks post treatment.

This is the “mystery” non-cosmetic indication for RT-002 that RVNC had promised to reveal.

RVNC holds its 3Q16 CC this afternoon at 4:30pm ET.